[{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Lovelace Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Belhaven Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Belhaven Biopharma \/ Lovelace Biomedical","highestDevelopmentStatusID":"4","companyTruncated":"Belhaven Biopharma \/ Lovelace Biomedical"},{"orgOrder":0,"company":"Belhaven Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Belhaven Biopharma","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Nasal Dry Powder","sponsorNew":"Belhaven Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Belhaven Biopharma \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Belhaven Biopharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BIO CEO & Investor
                          Not Confirmed
                          BIO CEO & Investor
                          Not Confirmed

                          Details : The financing from the proceeds will support the development of Nasdepi (epinephrine). It is being evaluated for the treatment of Anaphylactic reactions due to severe allergies.

                          Product Name : Nasdepi

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          January 22, 2025

                          Lead Product(s) : Epinephrine

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : $11.0 million

                          Deal Type : Financing

                          blank

                          02

                          RNA Therapeutics
                          Not Confirmed
                          RNA Therapeutics
                          Not Confirmed

                          Details : Nasdepi (epinephrine) a small molecule, dry powder nasal formulation is currently being investigated for the treatment of patients with anaphylactic reactions due to severe allergies.

                          Product Name : Nasdepi

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 09, 2024

                          Lead Product(s) : Epinephrine

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Lovelace Biomedical

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank